In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alkermes PLC

www.alkermes.com

Latest From Alkermes PLC

Major Depressive Disorder Patients Emphasize Long-Term Nature Of Disease In Feedback Meeting

Externally hosted patient focused drug development meeting in MDD brings timely messages to US FDA during period of active regulatory review of new applications. Patients stress need for fewer side effects to encourage long-term medication use, and also want fast-acting meds that can “jump start” lifestyle changes. 
Neurology Research & Development

Is Alkermes’ Schizophrenia Data Enough To Drive Demand?

Alkermes showed that combo pill ALKS 3831 offers a better weight gain profile compared to olanzapine in schizophrenia patients, but analysts differed on whether the benefit would be great enough to drive demand against entrenched generics.

Clinical Trials Neurology

Keeping Track Of Breakthrough Therapy Designations: Depression, Headaches, Hepatitis

The latest developments in one of the US FDA's favorite pathways.

Review Pathway Drug Review

Outcomes-Based Contracts May Be Negotiated By Michigan Medicaid

Michigan follows Oklahoma in gaining approval to negotiate supplemental rebates in the context of value-based contracts for drugs. Oklahoma now has four novel contracts in place.

Pricing Strategies Reimbursement
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Macromolecule
      • Pulmonary
  • Therapeutic Areas
  • Cancer
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Alkermes Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Ireland
  • Parent & Subsidiaries
  • Alkermes PLC
  • Senior Management
  • Richard F Pops, Chmn. & CEO
    James M Frates, SVP, CFO
    Blair C Jackson, SVP, Bus. Dev.
    Mark Stejbach, SVP, Chief Commercial Officer
    James Robinson, Pres. & COO
  • Contact Info
  • Alkermes PLC
    Phone: 1 772 8000
    1 Burlington Rd.
    Connaught House
    Dublin 4, MA
    Ireland
Advertisement
Advertisement
UsernamePublicRestriction

Register